← board
EMMA
distress 4/10 · elevated risk$0.010%today-32% from 52w high
Revenue
pre-revenue
Liquidity
$1M
Runway
1.7 yrs
Shares 1y
+10%
Price & events
-16.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+2.4%
1W
+4.1%
1M
+29.0%
3M
-16.1%
6M
-23.3%
1Y
-83.5%
2Y
-99.2%
5Y
-99.1%
All
Overview
- Market Cap
- $824.01K
- Enterprise Value
- $26.31M
- Volume
- 0
- 52 Week Range
- $0.01 – $0.02
- Total Shares
- 70.19M
- Float Shares
- 46.05M
- Short %
- 0.09%
- % Held by Insiders
- 47.08%
- % Held by Institutions
- 0.00%
- Beta
- 9.09
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-12-24partnershipEndari · Exclusive license to market, sell, and distribute Endari in US and Canada for sickle cell disease.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.